非小细胞肺癌中PD-1通路抑制联合颅内放疗的安全性
回顾性分析2013年8月至2016年9月163例晚期NSCLC脑转移患者,50例(31%)接受ICI治疗,113例(69%)未接受。不同颅内放疗类型下,ICI治疗与未治疗患者的所有级别及≥3级不良事件发生率无显著差异,且不良事件率与ICI相对于放疗的时序无关。结论认为ICI联合颅内放疗未显著增加放疗相关不良事件。
要点
- ICI联合颅内放疗未显著增加放疗相关不良事件。
- 立体定向放疗≥3级AE:ICI初治8% vs ICI治疗9%(p=1.00)。
- 全脑放疗≥3级AE:ICI初治8% vs ICI治疗10%(p=0.71)。
核心结论
- ICI治疗与颅内放疗联合未显著增加放疗相关不良事件,提示PD-1/PD-L1抑制剂在颅内放疗患者中安全性可接受。
研究设计与样本
- 回顾性研究,纳入2013年8月至2016年9月晚期NSCLC脑转移接受颅内放疗的患者163例,其中ICI治疗50例(31%),ICI初治113例(69%)。
主要发现
- 立体定向放疗≥3级AE发生率ICI初治8% vs ICI治疗9%(p=1.00)。
- 全脑放疗≥3级AE发生率ICI初治8% vs ICI治疗10%(p=0.71)。
- 不同颅内放疗类型下所有级别及≥3级AE发生率在ICI初治与ICI治疗患者间无显著差异。
- AE发生率与ICI给药相对于放疗的时序无关。
关键数值与推荐
- 94例(58%)接受立体定向放疗,28例(17%)接受部分脑放疗,101例(62%)接受全脑放疗,50%患者接受超过1个疗程放疗。
临床怎么用
- 晚期NSCLC脑转移患者接受颅内放疗时,可考虑联合PD-1/PD-L1抑制剂,但需进一步研究验证。
局限性
- 回顾性研究设计,样本量有限,需额外研究验证该策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Intracranial metastases are a common cause of morbidity and mortality in patients with advanced NSCLC, and are frequently managed with radiation therapy (RT). The safety of cranial RT in the setting of treatment with immune checkpoint inhibitors (ICIs) has not been established. METHODS: We identified patients with advanced NSCLC with brain metastases who received cranial RT and were treated with or without programmed cell death 1/programmed death ligand 1 inhibitors between August 2013 and September 2016. RT-related adverse events (AEs) were retrospectively evaluated and analyzed according to ICI treatment status, cranial RT type, and timing of RT with respect to ICI. RESULTS: Of 163 patients, 50 (31%) received ICIs, whereas 113 (69%) were ICI naive. Overall, 94 (58%), 28 (17%), and 101 (62%) patients received stereotactic radiosurgery, partial brain irradiation, and/or whole brain RT, respectively. Fifty percent of patients received more than one radiation course. We observed no significant difference in rates of all-grade AEs and grade 3 or higher AEs between the ICI-naive and ICI-treated patients across different cranial RT types (grade ≥3 AEs in 8% of ICI-naive patients versus in 9% of ICI-treated patients for stereotactic radiosurgery [p = 1.00] and in 8% of ICI-naive patients versus in 10% of ICI-treated patients for whole brain RT [p = 0.71]). Additionally, there was no difference in AE rates on the basis of timing of ICI administration with respect to RT. CONCLUSIONS: Treatment with an ICI and cranial RT was not associated with a significant increase in RT-related AEs, suggesting that use of programmed cell death 1/programmed death ligand 1 inhibitors in patients receiving cranial RT may have an acceptable safety profile. Nonetheless, additional studies are needed to validate this approach.
引用
- Hubbeling HG, Schapira EF, Horick NK, et al. Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29378267. doi:10.1016/j.jtho.2018.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。